Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.
Healthcare
What’s been agreed at this year’s World Health Assembly?
Streeting promises UK pharma quick action on VPAG frustration
UK life sciences venture capital funding lags behind
Public health strategies skip patients with rare diseases, says UK study
Fourth person receives eGenesis’ gene-edited pig kidney transplant
Neumora shares sink following Phase III flop in MDD
Investment surges, hurdles and emerging innovations in neuroscience
